GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cartesian Therapeutics
Shares of Cartesian Therapeutics, a company developing RNA cell therapy, reflect investors' faith in its innovative platform. Their price is highly volatile, dependent on news about clinical trials and the technology's potential for treating autoimmune diseases.
Share prices of companies in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a pioneer in RNA cell therapy, developing treatments for autoimmune diseases and oncology. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market views this cutting-edge, yet high-risk, biotech sector.
Broad Market Index - GURU.Markets
Cartesian Therapeutics is a pioneer in RNA cell therapy, developing treatments for autoimmune diseases and oncology. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market views this cutting-edge, yet high-risk, biotech sector.
Change in the price of a company, segment, and market as a whole per day
RNAC - Daily change in the company's share price Cartesian Therapeutics
For Cartesian, a cell therapy company, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials and technological breakthroughs. This metric forms the basis for analyzing biotech platforms on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Cartesian Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with RNAC's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cartesian Therapeutics is a biopharmaceutical company developing cell therapies. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating Cartesian's highly volatile stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cartesian Therapeutics
Cartesian Therapeutics, formerly known as Selecta Biosciences, has been developing a new generation of cell therapy for the past year. Its 12-month market cap is entirely dependent on clinical trial data for its RNA CAR-T therapy, which doesn't require debilitating chemotherapy for patients and can be manufactured directly in the clinic.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Cartesian Therapeutics, formerly Selecta Biosciences, is developing innovative RNA cell therapy. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the advanced biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
The ticker symbol RNAC belongs to Revolo Biotherapeutics, not Cartesian. Cartesian, as a biotech company focused on cell therapy, has stock performance that depends entirely on clinical trial results. Its chart isn't about economics, but about binary outcomes in the world of cutting-edge science and medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cartesian Therapeutics
The valuation of Cartesian, a cell therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its innovative RNA-CAR-T therapies, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a pioneer in RNA cell therapy, developing "off-the-shelf" drugs for the treatment of autoimmune diseases. This approach does not require individual genetic engineering of the patient's cells. The chart below reflects the mood in the cutting-edge cell therapy sector, where Cartesian is seeking its breakthrough.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cartesian Therapeutics is a biotech company developing RNA therapies for the treatment of autoimmune diseases. Its shares represent a venture bet on a new medical technology. Their performance is driven entirely by scientific data and clinical trial news, not by general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cartesian Therapeutics
Shares of Cartesian Therapeutics, a company developing next-generation cell therapy, are extremely volatile. Weekly price movements reflect news about the progress of clinical trials for their innovative approach to treating autoimmune diseases. The chart below illustrates how short-term scientific events shape value in cutting-edge biotech.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
How unique is Cartesian Therapeutics' performance in the biotech sector? This chart compares the weekly stock price movements of this RNA cell therapy company with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect broader sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cartesian Therapeutics develops cutting-edge cell therapy. This chart shows how disconnected its weekly performance is from the market. Its stock moves are driven by news about clinical trials and regulatory decisions, not macroeconomic data or overall stock market trends.
Market capitalization of the company, segment and market as a whole
RNAC - Market capitalization of the company Cartesian Therapeutics
Cartesian Therapeutics' market capitalization reflects its innovative approach to RNA cell therapy, which, unlike CAR-T, does not require complex gene modification. The company's valuation depends on the success of its clinical trials. The chart shows how investors value this potentially safer and more accessible technology.
RNAC - Share of the company's market capitalization Cartesian Therapeutics within the market segment - Oncology cell gene therapy
Cartesian Therapeutics (formerly Selecta Biosciences) is a company whose market share is based on its pioneering development of RNA cell therapies for autoimmune diseases. Its market capitalization reflects the potential of this new approach.
Market capitalization of the market segment - Oncology cell gene therapy
The chart illustrates the total value of biotech companies developing RNA cell therapies. Cartesian Therapeutics is one of the pioneers of this new approach. The chart's dynamics reflect how investors value this less toxic and potentially more versatile alternative to CAR-T.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a visualization of the market value of a new generation of cell therapy. Cartesian Therapeutics' market cap is a bet on its RNA technology, which could make treatment safer. The line shows how this scientific breakthrough, targeting autoimmune diseases, is vying for its share of the future of healthcare.
Book value capitalization of the company, segment and market as a whole
RNAC - Book value capitalization of the company Cartesian Therapeutics
Cartesian Therapeutics' book value represents its scientific and manufacturing capital. The chart below reflects the valuation of its patents for its RNA-modified cell therapy platform (RNA Armory®) and its manufacturing capacity. Growth in the pipeline reflects investments in the development of next-generation cell therapies.
RNAC - Share of the company's book capitalization Cartesian Therapeutics within the market segment - Oncology cell gene therapy
Cartesian Therapeutics' tangible assets include its state-of-the-art manufacturing facility and R&D centers for developing innovative RNA-modified cell therapies. The chart shows its stake in this advanced manufacturing infrastructure, which is key to next-generation cancer treatments.
Market segment balance sheet capitalization - Oncology cell gene therapy
Below you can see the overall book value of the biotech sector. Compared to this, Cartesian, which develops next-generation cell therapies, is capital-intensive. Producing "living drugs" requires complex and expensive cleanrooms and bioreactors.
Book value of all companies included in the broad market index - GURU.Markets
Cartesian Therapeutics is a pioneer in RNA cell therapy, a safer alternative to traditional CAR-T. The company's assets are not hospitals, but patents, a scientific platform, and manufacturing facilities. Their balance sheet is the value of a "factory" for creating "smart" but temporary cell therapies to fight cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cartesian Therapeutics
Cartesian's balance sheet consists of its cash and scientific platform. Its market capitalization, close to the value of its cash balances, shows that investors see little value in its RNA cell therapy technology after several strategic shifts. A chart showing MvsBCap_Co ≈ 1 indicates the company's "piggy bank" valuation.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Cartesian Therapeutics is developing RNA cell therapy—a new approach to treating autoimmune diseases. Its value lies in its cutting-edge scientific platform. The graph shows a high speculative estimate of its potential, which may offer a safer treatment than existing methods.
Market to book capitalization ratio for the market as a whole
Cartesian Therapeutics (formerly Selecta Biosciences) is developing a new approach to RNA cell therapy for autoimmune diseases. Its value lies in its scientific platform and potential to transform treatment approaches. This chart illustrates why investors are willing to pay a premium for innovative approaches in medicine.
Debts of the company, segment and market as a whole
RNAC - Company debts Cartesian Therapeutics
For Cartesian Therapeutics, a company developing cell therapies, debt is a vital source of funding. This chart shows how the company is raising capital to conduct clinical trials of its innovative treatments for autoimmune diseases. In this cutting-edge field of medicine, debt is an investment in the future.
Market segment debts - Oncology cell gene therapy
Cartesian Therapeutics is a biotech company developing RNA cell therapy, a safer alternative to DNA-based therapies. This is a cutting-edge scientific field. This chart shows how the company funds its innovative yet capital-intensive research, remaining at the forefront of cellular medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cartesian Therapeutics
Cartesian Therapeutics is developing innovative RNA cell therapy. This chart reflects the company's reliance on debt to fund its cutting-edge research. In the biotech sector, especially in such an emerging field, high debt means investors are betting on a scientific breakthrough that may never materialize.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Cartesian Therapeutics (formerly Selecta Biosciences) is developing RNA cell therapy for autoimmune diseases. This is a cutting-edge, but very expensive, area of medicine. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the entire cell therapy sector.
Debt to book value of all companies in the market
Cartesian Therapeutics (RNAC) is a pioneer in RNA cell therapy for autoimmune diseases. This is a cutting-edge and capital-intensive field of medicine. This chart shows the overall level of debt in the economy. It clearly demonstrates why Cartesian and similar companies are funded by shareholders rather than banks during the research stage.
P/E of the company, segment and market as a whole
P/E - Cartesian Therapeutics
This chart for Cartesian Therapeutics, a company developing next-generation cell therapy, is a measure of faith in its technology. There is no P/E ratio. Unlike traditional CAR-T, their approach does not require chemotherapy. The valuation is based on the potential of this safer treatment for autoimmune diseases and cancer.
P/E of the market segment - Oncology cell gene therapy
This chart illustrates the average P/E for biotech companies focused on cell therapy. For Cartesian Therapeutics, with its innovative approach, it serves as a backdrop. It shows how highly investors, on average, value the potential of this field, providing context for Cartesian's valuation, which promises to make therapy safer.
P/E of the market as a whole
Cartesian Therapeutics (formerly Selecta Biosciences) is developing a new generation of RNA cell therapies for the treatment of autoimmune diseases. Their approach aims to "reboot" the immune system without completely suppressing it. This risk appetite chart helps understand how investors evaluate cutting-edge approaches in immunology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cartesian Therapeutics
Cartesian Therapeutics is a biotech company developing RNA cell therapy for autoimmune diseases. Unlike traditional cell therapy, their approach does not require pre-treatment chemotherapy. This schedule reflects expectations for this safer and more accessible approach. Validation is contingent on the success of their technology in clinical trials.
%20P%2FE%20Cartesian%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cartesian-Therapeutics&v=1772547229045 "Chart of the company's future (projected) P/E Cartesian Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Cartesian Therapeutics is developing innovative RNA cell therapy for autoimmune diseases. This chart reflects the company's long-term profitability expectations. It demonstrates how highly the market values their potential to create a safer and more affordable alternative to traditional cell therapy for myasthenia gravis and other diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772547229055 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Cartesian Therapeutics is developing innovative RNA cell therapy for autoimmune diseases. This is a cutting-edge field of medicine. This market expectations chart reflects investor willingness to invest in fundamental science. Market optimism makes it easier for companies like Cartesian to raise capital for their research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772547229102 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cartesian Therapeutics
Cartesian Therapeutics is a biotechnology company developing RNA-based cell therapies, which avoid the risks associated with DNA modification. Its primary focus is the treatment of autoimmune diseases. Its financial results reflect investments in the development of a new, potentially safer class of cell therapy.
Profit of companies in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is developing a next-generation cell therapy (RNA CAR-T), which may be safer than existing ones. The company is in clinical trials. This graph illustrates how continuous innovation in biotechnology is shaping the future of medicine. The sector's profitability depends on the success of such advanced, yet risky, platforms.
Overall market profit
Cartesian Therapeutics is a biotech company developing RNA-based cell therapy, an innovative approach to treating autoimmune diseases. The company's success depends on clinical data and technological breakthroughs, not the state of the economy. Its performance is unrelated to the general trends that shape this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cartesian Therapeutics
Cartesian Therapeutics is developing an innovative RNA cell therapy for autoimmune diseases. This chart shows expectations based on the potential of its platform to offer a safer treatment than traditional cell therapy. Progress in clinical trials is the sole driver of these projections.
%20profit%20of%20the%20company%20Cartesian%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cartesian-Therapeutics&v=1772547229330 "Graph of future (projected) profit of the company Cartesian Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is developing innovative RNA therapy for autoimmune diseases. This chart shows the revenue forecast for the cell and gene therapy sector. It reflects expectations for breakthroughs in the treatment of autoimmune disorders. This background is important for assessing the potential of Cartesian's unique approach, which does not require extensive cell preparation.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772547229368 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Cartesian Therapeutics is developing innovative RNA cell therapy for the treatment of autoimmune diseases. Its future depends on scientific breakthroughs and clinical trial results. The economic backdrop illustrated here influences the level of public and private investment in cutting-edge science, which underpins the entire cell therapy industry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772547229372 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cartesian Therapeutics
Cartesian Therapeutics is developing an innovative RNA-based cell therapy for autoimmune diseases. Unlike DNA therapy, its approach does not permanently alter the genome. This chart shows how investors view this cutting-edge and potentially safer technology, which could revolutionize the treatment of complex diseases.
P/S market segment - Oncology cell gene therapy
Cartesian Therapeutics is a biotech company pioneering RNA cell therapy. Unlike traditional gene therapy, its approach does not alter DNA, making treatment potentially safer and more controllable. This chart shows the average valuation in the sector, helping to understand the market premium for this cutting-edge therapeutic platform.
P/S of the market as a whole
Cartesian Therapeutics is a biotech company developing a next-generation cell therapy (RNA CAR-T), a safer alternative to traditional DNA-based therapies. This cutting-edge science comes with a high risk. This market valuation chart helps understand the premium investors are paying for this potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotech company developing RNA cell therapies. This chart shows how investors view its innovative treatment approach and the likelihood of future commercial success.
%20P%2FS%20Cartesian%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cartesian-Therapeutics&v=1772547229507 "The graph of the company's future (projected) P/S Cartesian Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a biopharmaceutical company developing RNA cell therapies for autoimmune diseases. This chart compares market expectations for its future revenue with those of other oncology companies. The valuation reflects investor expectations for its innovative platform for creating safer cell therapies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772547229509 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Cartesian Therapeutics is developing RNA-based cell therapy, a new approach to treating cancer and autoimmune diseases. The company's valuation is a bet on future scientific success. Market optimism, evident in this chart, provides access to capital, which is vital to clinical testing of this cutting-edge but risky technology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772547229537 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cartesian Therapeutics
Cartesian Therapeutics is a biotech company developing RNA cell therapy for autoimmune diseases. Unlike traditional cell therapy, its approach does not require chemotherapy. Currently in clinical trials, the company's revenue comes from partnerships. The chart reflects funding for this cutting-edge therapeutic platform.
Sales of companies in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a biotech company developing a next-generation cell therapy (RNA CAR-T) for the treatment of autoimmune diseases. Unlike traditional CAR-T, its approach does not require chemotherapy and may be safer. This graph illustrates the potential for cell therapy applications beyond oncology, where autoimmune diseases represent a huge market.
Overall market sales
Cartesian Therapeutics is developing innovative RNA cell therapy. This is cutting-edge science, and the company's future depends on technological breakthroughs and successful clinical trials. This economic outlook impacts the stock market and investor appetite for funding such long-term, risky projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cartesian Therapeutics
Cartesian Therapeutics is developing an innovative RNA cell therapy for the treatment of autoimmune diseases. Unlike traditional cell therapies, their approach does not require pre-treatment chemotherapy. This graph reflects analysts' confidence in the potential of this new technology and its potential to transform the treatment of diseases such as myasthenia gravis.
%20sales%20of%20the%20company%20Cartesian%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cartesian-Therapeutics&v=1772547229656 "Schedule of future (projected) sales of the company Cartesian Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is developing RNA cell therapy for autoimmune diseases. This chart shows the outlook for the cell therapy sector, assessing whether the company's innovative, chemotherapy-free approach could become a safer and more effective alternative to existing treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772547229701 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Cartesian Therapeutics is developing innovative RNA cell therapy for autoimmune diseases. This schedule, reflecting investments in cutting-edge medical technologies, is critically important. Developing such a complex platform requires significant capital, and investor confidence, driven by the overall economic climate, determines the availability of funding.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772547229703 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cartesian Therapeutics
Cartesian Therapeutics is a biotech company specializing in the development of RNA-based cell therapies for the treatment of autoimmune diseases. Their approach promises greater safety than traditional gene therapy. This graph reflects the significant R&D costs associated with developing cutting-edge medical technology.
Market segment marginality - Oncology cell gene therapy
Cartesian Therapeutics (formerly Selecta Biosciences) is developing a new generation of RNA-CAR-T cell therapy. This approach could make the therapy safer and more accessible, allowing for outpatient treatment. This chart illustrates the scale of investment in this cutting-edge technology, which could change the paradigm for treating cancer and autoimmune diseases.
Market marginality as a whole
Cartesian Therapeutics is a biotech company developing RNA cell therapy that does not require genetic modification of a patient's cells outside the body. The overall profitability picture is irrelevant to them. Their value lies in the potential of their innovative platform. Success depends on demonstrating the safety and efficacy of this new approach.
Employees in the company, segment and market as a whole
Number of employees in the company Cartesian Therapeutics
Cartesian Therapeutics is a biotech company developing a new generation of RNA-based cell therapies. This graph shows the team of scientists working on this cutting-edge technology. The growth in staff reflects progress in clinical trials and investments in in-house manufacturing.
Share of the company's employees Cartesian Therapeutics within the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a pioneer in the development of RNA cell therapy, a new approach to cellular medicine. This chart shows the percentage of leading scientists in this breakthrough field that the company attracts. It illustrates its role as a leader in developing safer and more effective cell therapies for the treatment of cancer and autoimmune diseases.
Number of employees in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a biotech company developing RNA therapies for autoimmune diseases. This chart shows the growth of employment in this cutting-edge biotech field. The increase in scientists reflects progress in developing this innovative platform, which aims to "reboot" the immune system and offer new treatments without long-term immune suppression.
Number of employees in the market as a whole
Cartesian Therapeutics (formerly Selecta Biosciences) is developing a new type of cell therapy (CAR-T) for the treatment of autoimmune diseases. This revolutionary approach targets the root cause of the disease. This graph shows overall employment, and companies like Cartesian represent the cutting edge of biotechnology, creating a demand for unique specialists in the field of cell engineering.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cartesian Therapeutics (RNAC)
Cartesian Therapeutics, Inc. is a biotech company developing RNA cell therapy. This is a cutting-edge scientific field. This chart shows an extremely high market capitalization per employee, as the company's value is determined not by its current assets, but by the potential of its revolutionary platform. A small team of scientists is creating a technology that has the potential to transform medicine.
%20of%20the%20company%20Cartesian%20Therapeutics%20(RNAC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cartesian-Therapeutics-RNAC&v=1772547230122 "Chart of market capitalization per employee (in thousands of dollars) of the company Cartesian Therapeutics (RNAC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is a pioneer in RNA cell therapy for autoimmune diseases. This is a cutting-edge field of medicine. The chart shows the enormous premium the market commands for its unique technology. The high per-employee ratio reflects investors' faith in the ability of a small team of scientists to create a new standard of treatment.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772547230222 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Cartesian Therapeutics is developing innovative RNA cell therapy that may be safer than traditional approaches. Like many early-stage biotech companies, its value lies in its science. This chart shows a high market value per employee, reflecting the potential of its unique technology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772547230238 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cartesian Therapeutics (RNAC)
Cartesian Therapeutics (RNAC) is a biotech company developing RNA therapeutics for autoimmune diseases. This is cutting-edge R&D. This chart shows the "cost" of this innovative platform: it measures the negative profit (expenses) per scientist working to create the next generation of drugs.
%20Chart%20Cartesian%20Therapeutics%20(RNAC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cartesian-Therapeutics-RNAC&v=1772547230318 "Company Profit Per Employee (in thousands of dollars) Chart Cartesian Therapeutics (RNAC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Cartesian Therapeutics is developing RNA cell therapy for autoimmune diseases. Their approach promises to be safer, as it doesn't permanently alter the genome. This graph demonstrates the benchmark for biotech staff performance. It's important for assessing how effectively Cartesian's scientific team is implementing its unique approach.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772547230334 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Cartesian Therapeutics (RNAC) is a biotech company developing innovative RNA (rather than DNA) therapies to create cellular medicines directly in the patient's body. This is extremely complex, cutting-edge science. The graph doesn't show profit, but rather the high cost of R&D investment per scientist working on this futuristic technology platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772547230359 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cartesian Therapeutics (RNAC)
Cartesian Therapeutics is developing innovative RNA cell therapy for autoimmune diseases. This graph reflects its scientific focus. No revenue per employee is standard for a clinical-stage biotech company whose primary goal is to prove the safety and efficacy of its cutting-edge technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cartesian-Therapeutics-RNAC&v=1772547230443 "Sales chart per company employee Cartesian Therapeutics (RNAC)")
Sales per employee in the market segment - Oncology cell gene therapy
Cartesian Therapeutics (RNAC) (formerly Selecta) is a biotech company developing RNA-based cell therapies (non-transplant) for the treatment of autoimmune diseases. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their cutting-edge cell therapy R&D platform.
Sales per employee for the market as a whole
Cartesian Therapeutics (RNAC) is a biotech company developing next-generation cell therapy (CAR-T), but for autoimmune diseases, not cancer. It is a clinical-stage R&D company. This graph (close to zero) shows its investment in research: the company has no revenue, but it has a team of scientists working on breakthrough technology.
Short shares by company, segment and market as a whole
Shares shorted by company Cartesian Therapeutics (RNAC)
Cartesian Therapeutics (formerly Selecta) is a biotech company developing cell therapy (CAR-T) for the treatment of autoimmune diseases. This chart shows bearish bets. The shorts are driven by high risks: the technology is very complex, and the company has experienced clinical trial failures in the past.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cartesian-Therapeutics-RNAC&v=1772547230504 "Short Shares Chart for the Company Cartesian Therapeutics (RNAC)")
Shares shorted by market segment - Oncology cell gene therapy
Cartesian Therapeutics (RNAC) (formerly Selecta) is a biotech company developing CAR-T cell therapy for the treatment of autoimmune diseases. This chart shows the bets against the entire biotech sector. The rising bets against the industry reflect investor skepticism about the safety and commercial viability of this complex technology for treating non-cancer diseases.
Shares shorted by the overall market
Cartesian Therapeutics (RNAC) is a biotech company developing RNA therapies for autoimmune diseases. This is a cutting-edge, yet speculative, field. This chart of general fear shows investors fleeing "research projects." For RNAC, which has no profit, the market panic means a sharp drop in its stock price.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cartesian Therapeutics (RNAC)
Cartesian Therapeutics (formerly Selecta Bio) is a biotech company focused on cell therapy. The stock is highly volatile and dependent on R&D. This chart can surge above 70 on positive trial data or partnerships. Oversold levels (<30) are often associated with setbacks, delays, or a general downturn in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cartesian-Therapeutics-RNAC&v=1772547230644 "RSI 14 indicator chart for the company's stock Cartesian Therapeutics (RNAC)")
RSI 14 Market Segment - Oncology cell gene therapy
Cartesian Therapeutics is at the forefront of science, developing RNA-based (rather than DNA-based) cell therapies for the treatment of autoimmune diseases and cancer. This is a groundbreaking approach in medicine. This chart shows the overall "temperature" in the volatile gene and cell therapy sector. It helps separate the dynamics of RNAC from the general "hype" or "disappointment" in this complex field.
RSI 14 for the overall market
Cartesian Therapeutics (RNAC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RNAC (Cartesian Therapeutics)
Cartesian Therapeutics (formerly Selecta) is a biotech company developing allogeneic (off-the-shelf) RNA-CAR-T therapy that does not require upfront chemotherapy. This chart shows the average target price. Analysts' estimates are based on clinical data and the potential of this innovative cell platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RNAC-Cartesian-Therapeutics&v=1772547230921 "A chart showing analyst consensus forecasts for the expected stock price. RNAC (Cartesian Therapeutics)")
The difference between the consensus estimate and the actual stock price RNAC (Cartesian Therapeutics)
Cartesian Therapeutics (RNAC) is a biotech company developing allogeneic (donor) RNA cell therapy for autoimmune diseases (myasthenia gravis). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their advanced cell platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RNAC-Cartesian-Therapeutics&v=1772547231003 "A chart showing the difference between the consensus forecast and the actual stock price. RNAC (Cartesian Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Cartesian Therapeutics (RNAC) is a biotech company developing cell therapy (CAR-T) for the treatment of autoimmune diseases, not cancer. This chart shows general expectations for the oncology (and immunology) sector. It reflects whether experts believe in the application of "onco-technologies" in the treatment of autoimmune diseases.
Analysts' consensus forecast for the overall market share price
Cartesian Therapeutics (RNAC) is a biotech company developing RNA therapeutics for autoimmune diseases. This chart shows overall risk appetite. For Cartesian, which operates at the cutting edge of science (RNA therapeutics), overall market optimism (a rising chart) is critical to attracting the capital needed to fund expensive R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cartesian Therapeutics
Cartesian Therapeutics (RNAC) is a biotech company at the forefront of cell therapy. Unlike others, they use RNA engineering to create temporary (rather than permanent) CAR-T cells, which may be safer for treating autoimmune diseases. This chart is a clear indicator of faith in their unique R&D platform and reflects the market's appreciation of their clinical data.
AKIMA Market Segment Index - Oncology cell gene therapy
Cartesian Therapeutics (formerly Selecta Biosciences) develops cell therapy (CAR-T) for the treatment of autoimmune diseases, not cancer. This chart shows the average index for the cell therapy sector. It helps assess how Cartesian's innovative approach to CAR-T therapy compares to the industry average.
The AKIM Index for the overall market
Cartesian Therapeutics is a biotech company pioneering RNA-based cell therapy (rCAR-T) for the treatment of autoimmune diseases and cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative platform, offering a safer alternative to DNA therapy, compares to overall economic trends.
